Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

Background Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contribut...

Full description

Bibliographic Details
Main Authors: Teresa Amaral, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Domenico Mallardo, Paolo A Ascierto, Piotr Rutkowski, Jason John Luke, Mitchell P Levesque, Roberta Turiello, Elva Morretta, Maria Chiara Monti, Rosa Azzaro, Laurence Imhof, Marc Chevrier, Antje Sucker, Aldo Pinto, Silvana Morello
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001689.full

Internet

https://jitc.bmj.com/content/8/2/e001689.full

Similar Items